Meta-Analysis
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Sep 18, 2024; 12(3): 97256
Published online Sep 18, 2024. doi: 10.13105/wjma.v12.i3.97256
Incidence and predictors of hypocalcemia in end-stage renal disease patients on denosumab therapy: A systematic review and meta-analysis
Abdul Hannan Siddiqui, Misbah Shaikh, Afia Salman, Muhammad Ahmed Ali Fahim, Fizzah Batool, Tahreem Mari, Sarah Musani, Muneeb Fareed, Rooma Rehan, Amna Hassni, Urooj Nizami, Ayesha Amir, Abdul Moeed, Salim R Surani
Abdul Hannan Siddiqui, Misbah Shaikh, Afia Salman, Muhammad Ahmed Ali Fahim, Fizzah Batool, Tahreem Mari, Sarah Musani, Muneeb Fareed, Rooma Rehan, Amna Hassni, Urooj Nizami, Ayesha Amir, Abdul Moeed, Department of Internal Medicine, Dow University of Health Sciences, Karachi 74200, Sindh, Pakistan
Salim R Surani, Department of Medicine & Pharmacology, Texas A&M University, College Station, TX 77843, United States
Author contributions: Moeed A, Siddiqui AH, Fahim MAA, Salman A, and Surani SR participated in the conceptualization, data curation, investigation, methodology, project administration, resources, supervision, validation, visualization, and writing of the original draft; Shaikh M, Batool F, Mari T, Musani S, Fareed M, Rehan R, Hassni A, Nizami U, and Amir A were involved in project administration and writing of the original draft; Fahim MAA, Moeed A, Siddiqui AH, and Surani SR were involved in the formal analysis, project administration, supervision, validation, visualization, and writing, reviewing, and editing; All authors read and approved the final manuscript.
Conflict-of-interest statement: None of the authors have conflicts of interest to disclose.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abdul Moeed, Doctor, MBBS, Academic Editor, Doctor, Researcher, Department of Internal Medicine, Dow University of Health Sciences, Dow Medical College, Karachi 74200, Sindh, Pakistan. abdul.moeed19@dmc.duhs.edu.pk
Received: May 27, 2024
Revised: August 20, 2024
Accepted: August 26, 2024
Published online: September 18, 2024
Processing time: 108 Days and 15.6 Hours
Core Tip

Core Tip: Denosumab is a monoclonal antibody that inhibits receptor activator of nuclear factor kappa-Β-ligand and prevents bone resorption, making it useful for treating osteoporosis. Although denosumab has an acceptable safety profile, it is known to cause hypocalcemia in patients with renal insufficiency making it contraindicated in patients with hypocalcemia. Such patients may experience muscle and joint pain. To date, very few randomized controlled trials have explored the safety of this drug in patients with end-stage renal disease or on dialysis. This meta-analysis thus appraised the safety profile of denosumab in patients with end-stage renal disease.